1. This assessment is based on the Oxford criteria and the presence of toxic megacolon and clinical judgment. The assessment of these criteria is open to interpretation and may be subject to site and investigator interpretation. Block randomisation by study site may help address this but it is not stated whether clock randomisation is part of the randomisation strata.
2. The rescue rate of 49% in hospitalised patients is quite high (even though it is appreciated that this rate was derived from the CONSTRUCT recruitement data).
3. The drop-out rate may be higher that expected due to the short screening and treatment window as exclusion criteria that are not apparent on screening may develop (eg bacterial gastroenteritis)
Assessment
The study would have benefited from video endoscopy as entry and assessment criteria to reduce cohort heterogeneity and improve the accuracy of outcome measure.
General Comments and Safety aspects
Whilst there are good mechanistic reasons why anakinra may work in active IBD there appears minimal pilot data to show efficacy. Preliminary data appear limited to a case report ( Carter 2003) with worsening of CD and 3 cases of new onset UC after Anakinra (Hugle 2017).
Anakinra is well tolerated in published literature; however, high serious infection rates have been fund in RA literature in patients with concomitant steroids. This aspect of the IASO trial will therefore be particularly important to ascertain.
Whilst the drug-half life may be short, there may be ongoing effects on the immune system ( " immunological half-life") which may interact with infliximab or cyclosporin rescue therapies. The safety analysis of the first 20 patients will therefore be particularly important. , it is not clear that MTWSI will be measured every day for the 10 + days of the trial. The disease activity mentions measurement over the first 5 days. 4. Also, introduce the scales: EuroQol five dimensions; EQ-5D and Crohn's and ulcerative colitis questionnaire-32; CUCQ-32 and mention their validity. 5. Randomisation will be stratified for previous vs current therapy, it is not clear what the strata are and it is not clear how current is defined. For example if someone was using oral corticosteroid 3 days ago and has stopped, will he/she be considered current or past? List the strata for each stratifying variable and say how they are assessed. Also, discuss if you may have some patients who are neither current nor past oral corticosteroid, for example. 6. In the Method section it is stated that the 'trial will also feature a sub-study specifically examining the endoscopic effects of treatment with anakinra' It is not clear if the sub-study will be conducted only among the anakinra group. Clarify if this is the case or say: 'treatment with anakinra in comparison with placebo' 7. In the statistical section, it is stated that 'the primary analysis will consist of an estimate, of the absolute risk difference of the incidence rates between the two treatment arms, using logistic regression to adjust for important baseline covariates. The logistic regression does not provide absolute risk difference, but odds ratios. This needs to be corrected. Also, you need to justify why you need to adjust for confounders in a randomized, double-blind, clinical trial. 8. In Futility: the statement 'This is equivalent to spending 0.1% from the 15% total beta value set to control the type 2 error under the alternative hypothesis (49% and 29% rates)' is not clear, clarify and provide a reference. 9. 'We will employ the standard approaches to management of missing quality of life data previously described in the CONSTRUCT trial'. Provide examples for clarity. 
REVIEWER

GENERAL COMMENTS
Thank you for addressing all comments. Generally pragmatic trials are phase IV studies performed for treatment strategies with approved medications. For a drug like Anakinra which has minimal pilot data in IBD, I do not think a pragmatic trial as designed will be the "definitive" trial to change treatment. I recognize challenges with ASUC trials, but as we have learned from some promising but failed trials in IBD, standardization of patient enrollment and outcome assessment is critical to getting important information from a phase 2 trial.
